Covering medical care costs for participants in the eMERGE Network: Challenges for equity and implementation
- PMID: 40391568
- PMCID: PMC12318664
- DOI: 10.1016/j.gim.2025.101457
Covering medical care costs for participants in the eMERGE Network: Challenges for equity and implementation
Abstract
Purpose: To investigate the complexities of covering study-recommended medical care costs for individuals (in order to prevent lack of adherence due to financial reasons), which have received little attention.
Methods: We explored the deliberations, decisions, and challenges faced by the Electronic Medical Records and Genomics (eMERGE) Network during the implementation of a genomic research project recommending clinical care based on high-risk results defined largely by polygenic risk scores. Two surveys were disseminated to eMERGE sites: to identify preferences about payment for specific care recommendations (survey 1) and to understand the operational processes of covering medical care costs (survey 2).
Results: Paying for a subset of care recommendations for the funded study duration was identified as the most feasible approach for covering medical care costs for participants who received high-risk genomic results. Each eMERGE site, by necessity, used diverse approaches to pay for medical care costs.
Conclusion: eMERGE researchers balanced competing concerns about bias, equity, study design, regulatory compliance, and cost in designing a unified approach to cover some of the recommended medical care costs in the study. Many implementation challenges were encountered. Findings can inform researchers and regulatory bodies about the implications and complications of covering medical care costs in translational research studies focused on prevention.
Keywords: Genomic medicine; Research compliance; Research ethics; Study design; Translational genomics.
Copyright © 2025 American College of Medical Genetics and Genomics. All rights reserved.
Conflict of interest statement
Conflict of Interest Josh F. Peterson is a consultant to Myome; Elizabeth M. McNally is or has been a consultant to Amgen, Cytokinetics, PepGen, Tenaya and is a founder of Ikaika Therapeutics and these activities are unrelated to the content of this manuscript; Emma Perez is a paid consultant for Allelica Inc; and Maya Sabatello is a member of the Institutional Review Board of the All of Us Research Program. All other authors declare no conflicts of interest.
References
-
- NHGRI, https://grants.nih.gov/grants/guide/rfa-files/rfa-hg-19-013.html. Accessed August 2024.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources